Lead: A Nature Communications study introduced a Granzyme B‑mimetic nanozyme delivered in engineered nanovesicles that selectively induces apoptosis in cancer cells in preclinical models. Authors demonstrated that the synthetic enzyme surrogate reproduces proteolytic activity within tumor tissue and promotes tumor regression in murine experiments. The research team characterized pharmacokinetics, tumor uptake, and on-target proteolysis, reporting enhanced specificity versus untargeted controls and a manageable safety profile in dose-escalation animal studies. The nanozyme platform leverages tumor-targeting ligands to concentrate payload and minimize systemic exposure. Investigators positioned the approach as a modular platform for combining protease-mimetic nanotherapeutics with checkpoint inhibitors or standard chemotherapies; the paper calls for GLP toxicology studies to advance toward clinical translation.